Proxy contests and exempt solicitations in last 3 years
No recent proxy contest or exempt solicitation filings from shareholders.
Vote support at last AGM
On May 15, 2020, the Company held its 2020 Annual Meeting of Stockholders (the “Annual Meeting”). The following items of business were considered and voted upon at the Annual Meeting: (1) the election of two Class II directors named in the proxy statement related to the Annual Meeting; (2) the ratification of the selection of BDO USA LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020; (3) the approval of the 2020 Atossa Therapeutics, Inc. 2020 Stock Incentive Plan; (4) to conduct an advisory (non-binding) vote on the compensation of our named executive officers as described in the proxy statement related to the Annual Meeting.
The number of shares of common stock entitled to vote at the Annual Meeting was 9,130,984. The number of shares of common stock present or represented by valid proxy at the annual meeting was 6,206,823. All proposals passed. The number of votes cast for and against, and the number of abstentions and broker non-votes with respect to the matters voted upon at the Annual Meeting, are set forth below:
Election of two Class II Directors
The stockholders elected two Class II directors as set forth below:
Stephen J. Galli, M.D.
Richard I. Steinhart
Ratification of Auditors
The stockholders ratified the appointment of BDO USA LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2020 as set forth below:
Approve the Atossa Therapeutics, Inc. 2020 Stock Option and Incentive Plan and to Increase Authorized Shares under Option Plan
The stockholders approved the 2020 Stock Incentive Plan as follows:
Non-binding Vote on Executive Compensation
The stockholders approved an advisory non-binding vote on executive compensation as follows: